Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

The user experienced side effects from oral finasteride and switched to a DIY topical solution, then to Essegen F. They noticed increased hair shedding with the topical finasteride and are concerned about its normalcy and duration.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

The conversation is about a 21-year-old using finasteride, dermarolling, ketoconazole shampoo, hair growth serums, and exosome therapy to treat early-stage thinning on the crown. They are questioning if these treatments are sufficient to improve hair thickness.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

A 21-year-old MTF individual is experiencing rapid hair thinning and is currently on estradiol valerate. They are inquiring about the effectiveness of spironolactone for hair loss, despite being aware of its serious side effects.

Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The conversation discusses a hair loss treatment regimen involving a homemade topical solution of Minoxidil and Tretinoin, combined with Finasteride and microneedling. Users share advice on Tretinoin application, emphasizing gradual use to avoid skin irritation.

Exosome treatment for hair loss is viewed skeptically, with one person calling it a scam. Another suggests sticking with finasteride and minoxidil instead.